Wegovy works primarily through semaglutide, a GLP-1 receptor agonist that mimics a gut hormone involved in appetite and digestion.
How does semaglutide affect hunger signals?
Semaglutide binds to GLP-1 receptors in the brain, particularly in the hypothalamus, where it slows gastric emptying and strengthens satiety signals. This reduces daily food intake by 20-30% in clinical settings, creating a sustained calorie deficit.
What role does delayed gastric emptying play in long-term control?
It takes 4-5 hours instead of 2-3 hours for food to leave the stomach. The extended presence of food in the stomach sends ongoing signals to the brain through vagus nerve pathways, keeping patients feeling full between meals and after smaller portions.
Can patients build tolerance to Wegovy?
No widespread tolerance develops over two years of treatment. Trials show weight loss plateaus around week 60-68 but remains stable thereafter, with average losses of 15-20% of body weight maintained through year two.
What happens if patients stop taking Wegovy?
Weight regain begins almost immediately after discontinuation. Studies show 70% of lost weight returns within one year without continued treatment, confirming that the drug's effects depend on ongoing use rather than permanent metabolic reprogramming.
When does the patent expire for semaglutide?
The primary U.S. patent expires in 2031, with additional protections possibly stretching into 2032.